Anti-MRSA agent 28 is an antimicrobial compound effective against multidrug-resistant Gram-positive strains, with a minimum inhibitory concentration (MIC) of 0.06-0.125 μg/mL. It targets DNA polymerase IIIC to reduce the amount of genomic DNA, achieving an IC50 of 3.80 μg/mL. Anti-MRSA agent 28 exhibits potent antibacterial activity and aids in reducing inflammation, making it suitable for use against Gram-positive strains and in treating infectious diseases.

Anti-MRSA agent 28 (Compound 5a) exhibits antibacterial activity against gram-positive strains, including Staphylococcus aureus ATCC 33591 (MIC = 0.125 μg/mL), ATCC 700698 (MIC = 0.125 μg/mL), ATCC 700699 (MIC = 0.06 μg/mL), and ATCC BAA1708 (MIC = 0.125 μg/mL). At concentrations of 0.25 μg/mL to 4 μg/mL over 0 to 24 hours, it shows efficacy against Staphylococcus aureus ATCC 33591. The agent may inhibit genomic DNA dysfunction at 1 μg/mL for 1 hour and effectively influences genomic DNA quantity at 0.5 μg/mL to 4.5 μg/mL. Additionally, Anti-MRSA agent 28 binds DNA Pol-IIIC in a dose-dependent manner, with a KD value of 8.45 μM at a range of 6.25 μM to 50 μM, and inhibits the enzyme in Staphylococcus aureus ATCC 33591 at concentrations from 0 μg/mL to 16 μg/mL.

Anti-MRSA agent 28 (2% Vaseline; applied once daily for 3 days) significantly reduces bacterial count and systemic inflammation while effectively alleviating necrosis and infiltration and accumulation of neutrophils in infected tissues.